recent
year
develop
polyclon
monoclon
antibodi
mean
laboratori
anim
becom
vital
approach
protect
number
pathogen
contagion
marasco
sui
immunoprotect
molecul
provid
defens
transmiss
diseas
elimin
infect
prophylact
therapeut
protect
abil
first
discov
late
nineteenth
centuri
passiv
transmiss
antibodi
diseas
anim
provid
immun
diphtheria
subsequ
immun
sera
variou
herbivor
human
obtain
pool
use
therapeut
sinc
manag
infecti
diseas
diphtheria
tetanu
pneumococc
pneumonia
meningococc
mening
toxinmedi
diseas
consider
improv
patient
surviv
casadeval
antibodi
consist
two
heavi
chain
variabl
vh
join
jh
divers
constant
c
region
two
light
chain
variabl
vh
join
jh
constant
c
region
link
noncoval
bond
disulfid
ss
bridg
hamerscasterman
et
al
antibodi
bind
antigen
help
vhh
fragment
identifi
specif
uniqu
conform
epitop
presenc
long
complementari
determin
region
escherichia
coli
express
system
uniqu
valid
correct
function
antibodi
fragment
periplasm
space
cytoplasm
convers
periplasm
express
system
help
vh
vl
pair
provid
optim
condit
allow
product
function
molecul
sonoda
et
al
polyclon
antibodi
contain
larg
divers
concentr
differ
antibodi
unknown
specif
broadli
use
detect
differ
antigen
research
diagnost
howev
nonhuman
polyclon
antibodi
induc
immun
respons
human
imped
clinic
use
treat
snake
bite
wild
et
al
monoclon
antibodi
revolution
scientif
research
product
molecul
base
fusion
antibodi
gener
spleen
cell
immun
mice
rat
rabbit
immort
myeloma
cell
line
monoclon
antibodi
highli
specif
class
biolog
reagent
facilit
enhanc
clinic
diagnost
medic
arena
subsequ
variou
antibodi
use
clinic
prophylact
therapeut
agent
first
monoclon
antibodi
develop
hybridoma
technolog
report
subsequ
licens
milstein
nelson
develop
techniqu
signifi
novel
way
target
specif
mutat
nucleic
acid
provid
extens
express
diseas
condit
nelson
et
al
antibodi
product
primarili
depend
anim
immun
late
use
experiment
mice
rabbit
relat
laboratori
anim
wang
et
al
main
difficulti
product
applic
monoclon
antibodi
incompet
immun
respons
highli
toxic
conserv
antigen
furthermor
clinic
antibodi
human
origin
least
human
aspect
avoid
immunogen
reichert
therefor
transgen
mice
rabbit
human
antibodi
gene
develop
solv
immunogen
problem
necess
effect
immun
respons
immun
final
overcom
problem
human
antibodi
gener
vitro
antibodi
engin
technolog
phage
display
construct
antibodi
fragment
immunomodulatori
antibodi
cellfre
system
edward
express
recombin
antibodi
vitro
experienc
boost
advent
new
molecular
tool
use
variou
model
organ
yeast
bacteria
etc
new
techniqu
select
genet
engin
recombin
librari
use
phage
display
technolog
phage
display
techniqu
first
establish
georg
p
smith
valid
display
exogen
protein
filament
phage
fuse
peptid
interest
gene
iii
phage
first
recombin
antibodi
fragment
construct
bacteria
year
ago
roqu
et
al
goal
antibodi
product
technolog
achiev
hightit
highli
specif
highaffin
antisera
antigen
prepar
anim
immun
carri
follow
guidelin
product
techniqu
via
hybridoma
technolog
recombin
technolog
smith
moreov
therapeut
antibodi
develop
modul
fragment
crystalliz
fc
receptor
function
contribut
fc
glycan
immunoglobin
regul
antibodi
glycosyl
relat
immunoglobinsbas
therapeut
shade
anthoni
human
diseas
known
age
comfort
global
travel
better
interdepend
supplement
layer
intricaci
comprehend
infecti
diseas
life
threaten
contagion
effect
human
health
relat
unpredict
ill
death
interfer
mani
normal
life
activ
moreov
diseas
take
signific
human
toll
well
caus
public
fear
moren
fauci
date
limit
knowledg
avail
extend
aspect
product
antibodi
hybridoma
technolog
antibodi
engin
techniqu
construct
antibodi
fragment
display
technolog
extend
applic
fauci
moren
therefor
cope
health
threat
limit
extraordinari
advanc
hybridoma
technolog
antibodi
engin
techniqu
develop
countermeasur
diagnost
treatment
therapeut
antibodi
discuss
present
review
addit
widespread
antibodi
applic
describ
detail
pursu
healthier
futur
human
live
happi
life
antigen
interact
essenti
normal
function
antibodi
wide
use
research
therapeut
antigenspecif
membraneassoci
receptor
antibodi
respons
mediat
andor
b
cell
consequ
upon
bind
suitabl
antigen
b
lymphocyt
induc
prolifer
divid
number
activ
signal
thu
increas
number
b
cell
b
cell
differenti
specif
antibodi
produc
plasma
cell
clone
recogn
specif
antigen
epitop
via
antigen
receptor
b
cell
activ
recogn
specif
antigen
figur
andersen
et
al
antigen
highli
multifari
exhibit
abund
epitop
recogn
sever
lymphocyt
consequ
lymphocyt
multipli
differenti
activ
multifari
antigen
plasma
cell
produc
polyclon
antibodi
respons
mccullough
summerfield
polyclon
antibodi
pab
produc
rapidli
sever
month
compar
monoclon
antibodi
low
cost
low
technic
skill
stabl
broad
rang
ph
salt
concentr
addit
applic
therapeut
immunoglobulin
lipman
et
al
pab
recogn
multipl
linear
epitop
minim
conform
chang
contain
numer
antibodi
vari
affin
use
immunoprecipit
composit
antigen
form
larg
precipit
lattic
mice
use
often
produc
pab
small
size
blood
volum
altern
pab
produc
ascit
mice
moreov
antibodi
superior
specif
compar
monoclon
antibodi
gener
larg
number
bcell
clone
produc
antibodi
specif
epitop
hudson
et
al
zhuang
et
al
hybridoma
technolog
signific
essenti
platform
produc
highqual
mab
zhang
permit
gener
therapeut
antibodi
nativ
form
howev
technic
difficulti
hybridoma
product
updat
mainstream
antibodi
product
new
way
like
display
transgen
mice
techniqu
nevertheless
hybridoma
technolog
classic
establish
rout
gener
specif
antibodi
around
globe
glukhova
et
al
technolog
begin
immun
test
anim
antigen
interest
serum
antibodi
titer
determin
enzym
link
immunosorb
assay
elisa
subsequ
spleen
asept
remov
splenocyt
fuse
myeloma
cell
produc
hybridoma
cell
hybridoma
cell
cultur
plate
presenc
hypoxanthineaminopterinthymidin
hat
select
medium
high
throughput
screen
later
hybridoma
cell
produc
desir
antibodi
screen
convent
elisa
novel
nanoparticleprob
immunoassay
colloid
gold
silver
nanoparticl
figur
cell
cultur
system
vitro
specif
mab
cell
line
subject
mass
gener
media
select
shaker
flask
benchscal
bioreactor
ling
et
al
optim
condit
temperatur
percent
carbon
dioxid
humid
cell
cultur
determin
sen
roychoudhuri
transfer
pilot
scale
scalabl
toxicolog
studi
addit
clinic
materi
produc
larg
scale
exist
good
manufactur
practic
cgmp
regul
product
small
scale
product
alreadi
cultur
laboratori
transfer
pilot
scale
commerci
process
perform
character
scale
technolog
transfer
valid
commerci
cell
cultur
product
biolog
product
complet
pilot
scale
laboratori
method
li
et
al
recent
commerci
initi
process
character
scaleup
technolog
transfer
valid
manufactur
process
li
et
al
elisa
enzymebas
colorimetr
assay
requir
larg
sampl
volum
sever
incub
step
low
detect
sensit
tang
hewlett
convers
nanotechnolog
nanoparticl
np
use
nanomateri
length
scale
nanomet
nm
nanomateri
uniqu
biolog
properti
small
size
larg
surfacetovolum
ratio
sharp
melt
temperatur
magnet
properti
unusu
target
bind
properti
size
base
multicolor
qi
wang
np
gold
particl
use
improv
assay
sensit
specif
antibodi
low
limit
detect
lod
dose
respons
detect
sensit
compar
elisa
tang
hewlett
similarli
essenti
factor
np
select
nanometers
colloid
gold
silver
particl
conjug
target
ligand
includ
mab
peptid
small
molecul
function
structur
properti
avail
either
discret
molecul
bulk
materi
nanoparticl
probe
mab
use
target
antigen
interest
ling
et
al
use
colloid
gold
rapid
less
time
consum
cost
effect
techniqu
technolog
use
develop
immunochromat
strip
assay
base
mab
techniqu
widespread
applic
detect
number
antigen
exogen
antigen
endogen
antigen
autoantigen
neoantigen
viral
antigen
tumor
antigen
high
specif
bind
affin
schumach
schreiber
antigen
prepar
includ
qualiti
quantiti
essenti
product
antibodi
purif
antigen
difficult
time
consum
antigen
puriti
vital
adequ
immun
respons
leenaar
hendriksen
insignific
impur
immunodomin
case
variou
microbi
antigen
show
nonspecif
activ
antigen
interest
specif
activ
impur
higher
concentr
specif
antibodi
obtain
purif
exclus
impur
extens
absorpt
procedur
antibodi
affin
chromatographi
leenaar
et
al
mazzer
et
al
schedul
immun
antigen
contamin
consid
research
antigen
diluent
free
endotoxin
lipopolysaccharid
chemic
residu
util
neutral
microorgan
addit
ph
must
adjust
prevent
undesir
effect
anim
immun
hendriksen
hau
moreov
steril
work
condit
antigen
concentr
anim
prepar
inject
qualiti
must
confirm
condit
necessari
avoid
suppress
sensit
toler
superflu
immunomodul
induc
effect
immun
respons
requir
antigen
concentr
mg
base
intrins
properti
antigen
usual
dose
antigen
conjug
freund
adjuv
rabbit
rang
mice
goat
sheep
leenaar
et
al
inher
properti
antigen
quantiti
includ
purif
anim
immun
type
qualiti
adjuv
elicit
hightit
serum
respons
rout
immun
inject
frequenc
hanli
et
al
antibodi
product
involv
immun
inject
laboratori
anim
immunogen
protein
test
sampl
antiserum
immun
perform
specif
anim
speci
adjuv
process
form
immunogen
emuls
insolubl
water
leenaar
hendriksen
conjug
smaller
less
immunogen
antigen
ie
hapten
numer
myco
marin
toxin
carrier
protein
essenti
anim
inject
immun
anim
monitor
daili
three
time
week
side
effect
clinic
patholog
examin
sever
patholog
chang
tissu
reactiv
infect
anaphylact
reaction
case
booster
inject
report
absenc
visual
clinic
behavior
chang
leenaar
et
al
immun
rout
base
choic
anim
speci
adjuv
concentr
qualiti
paramet
antigen
apostolico
jde
et
al
suitabl
immun
rout
includ
subcutan
sc
intraderm
id
intramuscular
im
intraperiton
ip
intraven
iv
blood
sampl
handl
interfer
immun
site
avoid
pain
distress
anim
take
blood
sampl
leenaar
et
al
iv
rout
waterinoil
emuls
freund
complet
incomplet
adjuv
fca
fia
may
fatal
embol
caus
larg
particul
viscou
gel
adjuv
eg
aluminum
salt
occur
hanli
et
al
sc
administr
fca
immunolog
effect
ml
mice
ml
rabbit
report
patholog
chang
ip
administr
fca
suggest
antibodi
develop
induc
infect
periton
social
variat
high
risk
anaphylact
shock
booster
inject
iv
ip
rout
leenaar
et
al
volum
immunogen
mixtur
depend
qualiti
antigen
degre
lesion
form
therefor
smaller
volum
mixtur
inject
induc
antibodi
respons
except
increas
concentr
antigen
requir
leenaar
hendriksen
immun
volum
also
depend
anim
speci
rout
chemistri
inject
mixtur
volum
fca
lethal
effect
anim
physiolog
extent
lesion
produc
associ
high
volum
fca
ramosvara
miller
booster
inject
signific
effect
outcom
immun
induct
b
memori
cell
class
switch
b
cell
depend
time
interv
two
consecut
inject
small
volum
antigen
use
booster
inject
without
adjuv
leenaar
et
al
booster
inject
use
antibodi
titer
reach
plateau
begin
declin
antibodi
titer
typic
peak
week
immun
absenc
depotform
adjuv
use
first
immun
booster
inject
use
week
presenc
depotform
adjuv
fca
use
first
sc
inject
avoid
subsequ
mycobacteria
protein
sever
tissu
reaction
hendriksen
hau
hybridoma
technolog
essenti
product
highqual
mab
well
research
diagnost
reagent
current
rapidli
grow
class
therapeut
hnasko
stanker
mab
effect
screen
number
techniqu
elisa
phage
display
relat
technolog
screen
identifi
pick
specif
antibodi
produc
hybridoma
hybridoma
technolog
laboratori
anim
immun
antigen
interest
specif
antibodyproduc
b
cell
isol
spleen
fuse
immort
myeloma
cell
bradburi
et
al
subsequ
expans
clonal
popul
produc
serial
dilut
subclon
individu
hybridoma
cell
microtit
plate
next
hybridoma
supernat
check
elisa
relat
immunoassay
desir
antibodi
activ
el
deb
et
al
screen
hybridoma
cell
expand
bigger
well
cultur
flask
maintain
hybridoma
provid
suffici
cell
cryopreserv
supernat
later
investig
nelson
et
al
el
deb
et
al
howev
techniqu
restrict
number
clone
screen
thousand
consequ
insuffici
number
cell
remain
avail
clonal
expans
cell
immort
therefor
improv
techniqu
antigenbas
microarray
use
screen
clone
h
lithograph
fabric
microwel
individu
cell
compartment
nevertheless
techniqu
screen
bind
activ
allow
function
assay
el
deb
et
al
mab
character
base
determin
physicochem
immunochem
charact
heterogen
puriti
impur
biolog
activ
potenc
concentr
berkowitz
et
al
physicochem
properti
isotyp
class
subclass
light
chain
composit
primari
structur
mab
determin
immunolog
properti
includ
bind
assay
affin
avid
immunoreact
crossreact
structur
homolog
protein
analysi
cdr
epitop
character
determin
effector
function
chmp
heterogen
includ
chromatograph
electrophoret
method
quantiti
determin
character
mab
puriti
impur
contamin
concentr
specif
mab
also
check
peptid
map
antiidiotyp
immunoassay
potenc
appropri
method
use
determin
ident
biolog
activ
chmp
mabbas
product
exhibit
superior
specif
particular
antigen
characterist
featur
immunoglobin
make
ideal
tool
mani
applic
includ
diseas
diagnosi
therapi
tabl
modjtahedi
et
al
redman
et
al
steplewski
et
al
diagnost
applic
includ
biochem
analysi
imag
involv
number
immunoassay
detect
hormon
tissu
cell
product
imag
carri
use
radiolabel
mab
diagnost
infecti
diseas
therapeut
mab
wide
rang
applic
use
treatment
cancer
transplant
bone
marrow
organ
autoimmun
diseas
cardiovascular
diseas
variou
infecti
diseas
therapi
carri
direct
use
mab
therapeut
agent
target
agent
respect
modjtahedi
et
al
comput
bioinformat
approach
play
essenti
role
antibodi
select
epitop
predict
interdisciplinari
scienc
term
defin
applic
comput
tool
handl
biolog
inform
sever
comput
bioinformat
tool
predict
antibodi
binder
includ
rankpep
nhlapr
netmhc
kernelbas
interallel
peptid
bind
predict
system
kiss
support
vector
machin
svm
bhasin
raghava
lundegaard
et
al
moreov
tool
use
databas
contain
known
epitop
syfpeithi
mhcbn
lanl
iedb
protein
epitop
predict
soriaguerra
et
al
furthermor
tool
includ
posit
specif
score
matric
pssm
use
sequenc
align
iedb
analysi
resourc
databas
use
netmhcpan
peptid
affin
quantit
matric
qm
whole
antigen
process
pathway
wapp
matthew
correl
coeffici
mcc
spatial
epitop
predict
protein
antigen
seppa
soriaguerra
et
al
recent
simul
tool
cimmsim
develop
studi
number
differ
immunolog
process
process
includ
simul
immun
respons
repres
pathogen
well
lymphocyt
receptor
amino
acid
sequenc
b
cell
epitop
predict
rapin
et
al
differ
antibodi
fragment
use
phage
display
technolog
scfv
singl
chain
fragment
variabl
fv
fragment
variabl
fab
antigen
bind
fragment
deriv
vgene
domain
bispecif
bival
antibodi
oligom
figur
nelson
fab
fragment
linkag
disulfid
bridg
radiolabel
fab
use
tumor
imag
fv
use
construct
vl
vh
domain
modif
scfv
popular
fragment
linker
use
stabil
proper
antigen
bind
site
format
without
loss
antibodi
affin
chelat
recombin
antibodi
crab
scfv
segment
high
bind
affin
construct
consist
two
scfv
fragment
specif
ident
antigen
adjac
epitop
fragment
connect
short
linker
amino
acid
dimer
format
diabodi
wright
deonarain
nelson
phagedisplay
antibodi
librari
wide
use
construct
highaffin
targetspecif
antibodi
chen
et
al
scfv
noncoval
heterodim
consist
vh
vl
domain
moreov
antibodi
repertoir
phagedisplay
librari
construct
harvest
messeng
ribonucl
acid
mrna
peripher
blood
lymphocyt
hybridoma
spleen
bone
marrow
tonsil
similar
sourc
chen
et
al
larg
librari
divers
rang
antibodi
gene
creat
use
revers
transcrib
rt
process
cdna
function
templat
antibodi
gene
amplif
pcr
lim
et
al
librari
also
creat
pcr
assembl
phagemid
sequenti
clone
combinatori
infect
vh
vl
chain
combin
linker
orient
depend
clone
construct
combinatori
scfv
librari
antigen
select
ahmad
et
al
anoth
techniqu
recombin
antibodi
product
util
phage
recombin
display
antibodi
tip
undergo
biopan
vitro
select
scfv
larg
librari
variabl
domain
circumv
tradit
hybridoma
method
numer
scfv
fragment
construct
hapten
wang
et
al
protein
carbohydr
receptor
tumor
antigen
medic
therapi
diagnost
applic
wang
et
al
phage
display
power
biolog
techniqu
screen
specif
peptid
protein
screen
antibodi
librari
phage
display
permit
rapid
select
scfv
isol
vh
vl
chain
mab
transform
thu
therapeut
antibodi
noxiou
highli
conserv
antigen
plasma
membran
protein
receptor
obtain
nativ
conform
avoid
anim
immun
rader
barba
peptid
librari
incub
plate
coat
antigen
interest
next
unbound
phage
wash
away
phage
amplifi
use
host
bacteria
highaffin
elut
bindingamplif
cycl
expand
pool
favor
bind
sequenc
final
individu
clone
character
round
dna
sequenc
elisa
achiev
result
structur
function
detail
catanes
et
al
numer
express
system
e
coli
yeast
mammalian
insect
cell
wheat
germ
cellfre
express
system
plantbas
express
system
use
success
isol
scfv
display
fragment
wang
et
al
express
activ
scfv
perform
appropri
fold
vitro
refold
aggreg
express
system
product
activ
scfv
antibodi
select
design
construct
base
host
bacteri
express
system
suitabl
wide
use
method
product
scfv
antibodi
fragment
compar
avail
express
strategi
frenzel
et
al
e
coli
valuabl
tool
express
system
field
genet
biochemistri
system
numer
advantag
includ
enhanc
fold
low
cost
high
throughput
wellstudi
physiolog
genet
rapid
growth
high
yield
total
cellular
protein
simpl
handl
addit
use
multiplex
clone
express
purif
protein
structur
genom
rosano
ceccarelli
antibodi
character
involv
peptid
map
glycan
character
analysi
purif
fragment
antibodi
pharmacokinet
qualiti
assur
mani
applic
basic
research
roth
et
al
scfv
antibodi
usual
character
affin
isotyp
cross
bind
phageelisa
immunoblot
biochem
character
includ
express
scfv
antibodi
solubl
form
infect
e
coli
cell
addit
character
carri
immunofluoresc
antibodi
test
ifat
mass
spectrometri
sequenc
indirect
immunofluoresc
ifi
assay
cytotox
analysi
surfac
plasmon
reson
nmr
spectroscopi
wang
et
al
yuasa
et
al
levenhagen
et
al
fab
antibodi
fragment
smaller
better
tissu
tumor
penetr
intact
mab
fab
lack
constant
region
therefor
antibodi
effector
function
nelson
moreov
fab
bind
specif
antigen
use
nonclin
studi
eg
stain
experi
clinic
therapeut
pegyl
fab
fragment
fragment
day
serum
halflif
use
improv
antitumor
activ
reduc
immunogen
chame
et
al
tumor
necrosi
factor
tnf
interleukin
proinflammatori
cytokin
caus
multifactori
diseas
cancer
system
inflamm
moreov
factor
involv
redund
diseasemedi
crosstalk
signal
cascad
arango
duqu
descoteaux
similarli
upregul
altern
receptor
pathway
switch
often
relat
resist
therapi
dong
et
al
obstruct
sever
target
multipl
site
one
target
associ
improv
therapeut
efficaci
past
decad
dual
target
bispecif
antibodi
gradual
switch
combinatori
cocktail
therapi
target
techniqu
base
target
multipl
diseasemodifi
reagent
one
drug
sever
bispecif
molecul
diabodi
igglik
tetraval
didiabodi
iggscfv
fusion
protein
bispecif
develop
target
tumor
mediat
receptor
member
epiderm
growth
factor
egf
receptor
famili
ie
egfr
insulinlik
growth
factor
receptor
tao
et
al
kontermann
brinkmann
applic
singl
bispecif
molecul
advantag
less
complic
administ
patient
requir
reduc
preclin
clinic
test
cost
effect
manufactur
kontermann
brinkmann
smaller
antibodi
fragment
permit
depth
tissu
penetr
associ
affin
antibodi
fragment
moreov
high
concentr
complet
antibodi
restrict
abil
infiltr
tumor
weiner
adam
addit
engin
antibodi
fragment
includ
cdr
fab
f
ab
monospecif
bispecif
trispecif
monoval
igg
bispecif
diabodi
trispecif
triabodi
scfvfc
minibodi
new
antigen
receptor
ignar
variabl
new
antigen
receptor
vnar
domain
shark
camelid
heavi
chain
igg
hcigg
vhh
nelson
rodrigo
et
al
filament
bacteriophag
use
phage
display
techniqu
virus
belong
inovirida
famili
fewer
filament
phage
genu
compar
tail
phage
inoviru
virion
mm
diamet
contain
circular
dna
enclos
protein
capsid
infect
gram
neg
posit
bacteria
lyse
host
cell
instead
pack
extrud
surfac
marvin
et
al
genom
virus
consist
doubl
strand
dna
dsdna
singl
strand
dna
ssdna
doubl
strand
rna
dsrna
singl
strand
rna
ssrna
virus
enter
host
cell
via
pilli
involv
genom
replic
virion
structur
assembl
regul
stassen
et
al
virus
undergo
extens
recombin
act
vector
phagemid
gene
transfer
close
relat
phenotyp
genotyp
integr
host
genom
phageencod
transposas
hostencod
xercd
hassan
et
al
filament
phage
three
distinct
class
includ
fd
infect
e
coli
protein
display
phage
protein
piii
fusion
pviii
preserv
function
coupl
residu
hess
et
al
phage
easili
manipul
due
small
genom
therefor
beststudi
virus
extens
use
phage
display
technolog
larg
phage
particl
produc
insert
dna
nonessenti
region
stabl
extrem
condit
produc
high
amount
et
al
phage
display
technolog
facilit
product
protein
librari
form
larg
number
phage
particl
display
differ
molecul
differ
ligand
popul
phage
molecul
specif
binder
screen
biopan
allow
enrich
desir
molecul
bazan
et
al
first
step
incub
display
librari
immobil
surfac
exampl
micropl
magnet
bead
column
matrix
pvdf
membran
immunotub
entir
cell
nonbind
phage
remov
extens
wash
binder
elut
acid
salt
buffer
binder
amplifi
use
appropri
bacteri
host
cell
e
coli
obtain
highaffin
target
five
round
biopan
perform
figur
final
dna
sequenc
primari
structur
carri
produc
individu
clone
target
protein
bazan
et
al
wu
et
al
mani
factor
includ
proper
biopan
design
type
immobil
surfac
bind
time
wash
antigen
concentr
affect
level
select
screen
antibodi
uniqu
epitop
bazan
et
al
numer
screen
cycl
essenti
biopan
attain
prefer
bind
activ
acquir
monoclon
phage
antibodi
sever
test
includ
elisa
fluorometr
microvolum
assay
technolog
fmat
chromophoreassist
laser
inactiv
cali
use
analyz
activ
tonelli
et
al
variou
type
phage
librari
use
screen
specif
recombin
proteinsantibodi
relat
antigen
specif
construct
specif
highaffin
antibodi
librari
specif
antigen
use
immun
anim
dissoci
constant
nanomolar
rang
singlepot
gener
nonspecif
librari
produc
antigen
construct
secondari
mutant
antibodi
phage
librari
screen
antibodi
high
specif
hust
dubel
develop
antibodi
librari
immun
anim
becom
obsolet
construct
divers
univers
singlepot
librari
isol
numer
antigen
pdt
mani
applic
biotechnolog
product
recombin
multifunct
antibodi
cancer
immunotherapeut
enhanc
valid
protein
fragment
yau
et
al
larg
number
antibodi
reagent
develop
hematolog
applic
cell
subpopul
identif
direct
therapeut
vivo
imag
antiabo
antirh
antikel
hemagglutin
antibodi
develop
red
blood
antigen
mark
et
al
antirh
antihpaia
bispecif
diabodi
develop
pdt
use
hemagglutin
assay
diabodi
use
treatment
neonat
alloimmun
thrombocytopenia
watkin
et
al
moreov
variou
antibodi
reagent
rais
fetal
red
blood
cell
huie
et
al
addit
techniqu
help
product
antibodi
dendrit
cell
white
blood
cell
wbc
fit
et
al
hairi
cell
leukemia
kreitman
et
al
myeloma
protein
paraprotein
onuallain
et
al
b
cell
maeda
et
al
clot
factor
aitp
gpia
gpiiia
antigen
cd
antigen
chu
et
al
antigen
siegel
et
al
human
immun
librari
develop
pdt
facilit
studi
autoimmun
neurolog
disord
physiolog
clinic
diagnost
treatment
aitp
platelet
disord
caus
antiplatelet
autoantibodi
ms
myasthenia
gravi
mg
antibodi
nicotin
acetylcholin
receptor
acchor
thrombot
thrombocytopen
purpura
ttp
cogan
syndrom
cs
caus
system
vascul
acut
anterior
uveiti
aau
ocular
inflamm
insulin
depend
diabet
mellitu
iddm
caus
destruct
pancreat
beta
cell
wegen
granulomatosi
finnern
et
al
autoimmun
thyroid
diseas
latrofa
et
al
primari
biliari
cirrhosi
pbc
syndrom
ss
addit
techniqu
therapeut
use
blister
skin
diseas
pemphigu
vulgari
pv
payn
et
al
pemphigu
foliaceu
pf
ishii
et
al
autoimmun
hepat
aih
primari
biliari
cirrhosi
pbc
mix
cryoglobulinemia
cryoii
system
sclerosi
ssc
autoimmun
cholang
aic
antiphospholipid
syndrom
ap
vitiligo
rheumatoid
arthriti
crohn
diseas
grave
diseas
gd
celiac
diseas
genet
inflammatori
disord
zohreh
hossein
neurolog
disord
treat
intracellular
antibodi
fragment
intrabodi
potenti
therapeut
intrabodi
select
abnorm
intracellular
protein
howev
sever
limit
extracellular
bind
intern
dna
transfect
viral
base
vector
lipofect
electropor
jazi
et
al
effici
vivo
techniqu
alter
cell
viabil
problem
overcom
fuse
protein
transduct
domain
ptd
antibodi
langedijk
et
al
phage
display
librari
util
novel
immunotherapeut
strategi
treatment
neurotoxin
diseas
cjd
syndrom
gss
also
use
kuru
diseas
famili
fatal
insomnia
accumul
abnorm
prion
protein
prpsc
thanongsaksrikul
chaicumpa
huntington
diseas
parkinson
diseas
moreov
employ
inhibitori
studi
format
enzym
therapi
brain
vasculatur
brain
parenchyma
chen
et
al
biopan
vivo
phage
display
librari
facilit
isol
peptid
home
type
organ
human
bodi
phage
display
appli
stem
cell
cell
base
regen
medicin
gothard
et
al
moreov
techniqu
assist
guid
deliveri
variou
peptidesdrug
proapoptot
peptid
cytotox
drug
metalloproteas
inhibitor
cytokin
specif
target
nixon
et
al
bind
peptid
extracellular
domain
receptor
associ
hypertens
atherogenesi
nixon
et
al
studi
report
home
rgdmotifcontain
peptid
angiogen
vasculatur
link
proapoptot
peptid
success
use
treatment
collageninduc
arthriti
mice
phage
librari
also
use
antiobes
microparticl
mp
integrin
angiogenesi
therapi
target
vascular
endotheli
growth
factor
vegf
cook
et
al
similarli
phage
display
use
tumor
target
agent
eg
scfv
molecul
specif
carcino
embryon
antigen
cea
edward
et
al
techniqu
replac
radiolabel
antibodi
multipl
disadvantag
includ
reduc
natur
immun
adachi
et
al
furthermor
pdt
use
isol
number
peptid
molecular
imag
advantag
small
size
rapid
blood
clearanc
lack
immunogen
tissu
penetr
increas
diffus
numer
peptid
tumor
target
isol
use
human
b
cell
lymphoma
mcguir
et
al
cervic
robinson
et
al
colon
rasmussen
et
al
gastric
liang
et
al
breast
askoxylaki
et
al
lung
chang
et
al
glioblastoma
wu
et
al
hepat
du
et
al
prostat
zitzmann
et
al
neuroblastoma
askoxylaki
et
al
thyroid
zitzmann
et
al
carcinoma
cell
cultur
howev
peptid
report
function
vivo
inact
observ
peptid
recogn
mous
doubl
minut
protein
pazgier
et
al
receptor
zurita
et
al
prostat
specif
antigen
psa
pakkala
et
al
heat
shock
protein
kim
et
al
growth
factor
hetian
et
al
hybridoma
technolog
wellestablish
method
gener
murin
mab
cell
line
fusion
splenocyt
harvest
immun
mice
myeloma
cell
technolog
remain
feasibl
method
laboratori
implement
basic
cell
biolog
research
hybridoma
technolog
compar
simpl
procedur
minim
cost
steadi
product
nativ
whole
immunoglobulin
tomita
tsumoto
nevertheless
technolog
variou
limit
antibodi
produc
hybridoma
techniqu
strictli
murin
protein
limit
therapeut
use
human
addit
also
trigger
human
antimous
antibodi
hama
respons
tjandra
et
al
moreov
indefinit
product
cost
low
fusion
effici
limit
number
mab
difficulti
develop
mab
strictli
conserv
toxin
antigen
time
consumpt
disadvantag
hnasko
stanker
product
amplif
antibodi
vitro
use
bacteria
pdt
low
turnaround
time
compar
method
addit
librari
compris
divers
variant
select
vari
rang
biolog
inorgan
target
sblattero
bradburi
experiment
condit
control
requir
equip
librari
avail
commerci
disadvantag
includ
difficult
procedur
lack
antibodi
display
surfac
bacteriophag
yield
small
number
mab
willat
immunomodulatori
techniqu
persist
progress
expand
clinic
efficaci
therapeut
antibodi
cell
surfac
antigen
exhibit
wide
array
target
overexpress
mutat
select
express
select
modul
antibodybas
therapeut
technolog
function
engin
alter
antigen
receptor
function
immun
system
ie
alter
fc
function
cell
activ
antibodi
conjug
drug
deliveri
system
dd
target
specif
antigen
immunomodulatori
antibodi
gain
signific
clinic
success
scott
et
al
fc
region
modul
engin
effector
function
exampl
increas
lessen
bind
fc
gamma
receptor
complement
factor
halflif
igg
halflif
extend
improv
affin
fc
fc
neonat
receptor
fcrn
moreov
prolong
engin
phdepend
antigen
bind
enhanc
recycl
igg
via
fcrn
effect
bind
target
molecul
engin
fc
region
permit
develop
molecul
better
suit
pharmacolog
activ
requir
vincent
zurini
rath
et
al
recent
studi
investig
engin
phdepend
interact
igg
fcrn
involv
modul
constant
fc
part
monoclon
human
antibodi
improv
effector
function
clinic
efficaci
nextgener
therapeut
grevi
et
al
similarli
new
opportun
creat
develop
antibodydrug
conjug
adc
treat
infecti
diseas
target
cancer
cell
adc
develop
progress
antibodi
gener
select
exceedingli
cytotox
molecul
construct
stabl
linker
investig
clinic
trial
vincent
zurini
cytotox
therapeut
mab
often
help
target
cellkil
elicit
immun
effector
function
includ
antibodydepend
cellmedi
cytotox
adcc
antibodydepend
cellular
phagocytosi
adcp
mediat
innat
immun
effector
cell
complementdepend
cytotox
cdc
mediat
humor
compon
figur
vitro
studi
fc
engin
method
specif
design
modul
adcc
adcp
cdc
envis
therapeut
mediat
kinder
et
al
natur
killer
nk
cell
exhibit
essenti
role
immun
context
mab
treatment
exert
direct
cytotox
toward
infect
tumor
cell
contribut
model
adapt
respons
cheng
et
al
sever
nkcell
modul
ipilimumab
nivolumab
approv
treatment
metastat
melanoma
berman
et
al
fcengin
antibodi
improv
adccadcp
potenti
target
consequ
enhanc
therapeut
potenti
mab
nk
cell
exclus
exhibit
lowaffin
activ
inhibitori
antibodi
receptor
featur
substanti
role
adcc
sever
studi
establish
link
activ
fc
receptor
efficaci
mab
therapi
use
mous
tumor
model
romain
et
al
recent
glycoengin
techniqu
use
produc
recombin
therapeut
protein
optim
efficaci
halflif
specif
antigen
glycoengin
express
platform
progress
document
essenti
approach
advanc
biopharmaceut
ferrermiral
et
al
dicker
strasser
techniqu
appli
vivo
express
system
includ
mammalian
cell
insect
cell
yeast
plant
product
recombin
protein
underlin
approach
aim
develop
glycoprotein
homogen
n
olink
glycan
defin
composit
dicker
strasser
moreov
multilevel
glycoengin
techniqu
investig
gener
igg
defin
fcglycan
eukaryot
cell
dekker
et
al
addit
e
coli
express
success
employ
produc
recombin
human
kamionka
antibodi
engin
superior
properti
bind
affin
stabil
catalyt
activ
sever
display
tool
exampl
yeast
bacteri
display
broad
spectrum
biotechnolog
medicin
biomed
applic
yeast
surfac
display
exhibit
develop
recombin
antibodi
display
surfac
saccharomyc
cerevisia
via
genet
fusion
abund
cell
wall
protein
cherf
cochran
yeast
display
techniqu
use
engin
protein
affin
stabil
enzymat
activ
moreov
extens
appli
protein
epitop
map
identif
proteinprotein
interact
use
display
protein
industri
medicin
cherf
cochran
sever
recombin
antibodi
gener
yeast
display
lethal
infect
highli
pathogen
avian
influenza
viru
lei
et
al
cell
tumor
li
et
al
human
tumor
endotheli
marker
yuan
et
al
similarli
sever
bacteri
display
system
establish
gramneg
bacteria
gramposit
bacteria
lee
et
al
display
system
compris
carrier
protein
anchor
motif
target
protein
host
strain
protein
develop
use
anchor
motif
includ
outer
membran
protein
lipoprotein
autotransport
subunit
surfac
appendag
slayer
protein
han
lee
bacteri
display
widespread
applic
includ
live
vaccin
develop
screeningdisplay
peptid
librari
biosorb
wholecel
biocatalyst
biosensor
develop
moreov
promis
technolog
help
remedi
pollut
biofuel
product
product
enantiomer
pure
compound
han
lee
ramanan
et
al
ribosom
display
cellfre
display
system
techniqu
perform
entir
vitro
select
protein
peptid
bind
desir
ligand
ribosom
display
consist
prokaryot
eukaryot
display
system
zahnd
et
al
form
stabl
proteinribosomemrna
prm
complex
link
individu
nascent
protein
phenotyp
analog
messeng
rna
mrna
genotyp
ribosom
display
allow
synchron
isol
function
nascent
protein
affin
ligand
togeth
encod
mrna
encod
mrna
transform
amplifi
dna
manipul
includ
repeat
cycl
protein
express
advantag
ribosom
display
cell
base
method
includ
display
larg
librari
gener
toxic
proteolyt
sensit
unstabl
protein
incorpor
modifi
amino
acid
mutat
distinct
posit
taussig
zahnd
et
al
ribosom
display
system
investig
identifi
potenti
antigen
clonorchi
sinensi
kasi
et
al
human
tumor
necrosi
factor
diagnosi
treatment
zhao
et
al
larg
size
mab
limit
tumor
penetr
long
serum
halflif
suitabl
therapi
imag
applic
therefor
antibodi
fragment
construct
variou
format
small
monoval
penetr
tumor
tissu
effici
rapidli
elimin
renal
clearanc
chame
et
al
similarli
recombin
antibodi
sever
advantag
bacteria
yeast
plant
anim
use
produc
antibodi
ii
need
immun
iii
intrins
properti
immunogen
bind
affin
pharmacokinet
specif
stabil
antibodi
modifi
easili
use
mutagenesi
techniqu
genet
engin
antibodi
integr
characterist
suit
variou
downstream
applic
convert
function
whole
immunoglobulin
bradburi
et
al
antibodi
exhibit
strong
immun
defend
foreign
antigen
nonselfag
howev
varieti
recombin
antibodi
need
interact
hostil
antigen
last
decad
use
antibodi
engin
recombin
antibodi
technolog
shape
genet
manipul
divers
rang
antibodi
fragment
research
diagnosi
therapi
kontermann
muller
technolog
result
better
affin
specif
manipul
antibodi
fragment
facilit
replac
hybridoma
technolog
variou
display
system
unlimit
antibodi
product
known
antigen
gram
et
al
convers
engin
antibodi
variou
disadvantag
exhibit
greater
expens
complex
manufactur
compar
antibodi
develop
hybridoma
technolog
spiess
et
al
due
foreign
natur
engin
therapeut
antibodi
lead
allotyp
immun
respons
result
rapid
clearanc
bodi
kidney
elicit
tcell
help
reduc
antibodi
avid
moreov
engin
antibodi
exhibit
reduc
halflif
due
lack
fc
domain
prevent
fcrnmediat
recycl
likewis
antibodi
base
therapi
limit
base
fact
mani
target
sometim
low
level
yet
determin
variou
diseas
chame
et
al
attarwala
elisa
common
method
quantit
patholog
antigen
case
modifi
elisa
use
combin
variou
specif
proteinspeptid
rapid
consist
rel
easi
analyz
adapt
highthroughput
screen
alonso
et
al
princip
specif
antibodi
immobil
high
bind
elisa
plate
incub
overnight
h
follow
wash
pbst
mm
nacl
mm
kcl
mm
mm
tween
murayama
et
al
plate
block
irrelev
protein
eg
albumin
exampl
pb
contain
skim
milk
incub
overnight
h
wash
sampl
standard
dilut
ad
well
captur
bound
protein
incub
h
wash
properli
next
specif
peroxidaseconjug
enzym
label
detect
antibodi
ad
well
enabl
detect
captur
protein
incub
h
appropri
wash
colorimetr
substrat
ad
well
incub
min
color
develop
catalyz
enzym
instanc
addit
tmb
substrat
develop
blue
color
read
micropl
plate
reader
wavelength
nm
addit
addit
sulfur
acid
stop
reaction
solut
develop
yellow
color
read
nm
correspondingli
addit
incub
condit
reagent
formul
prefer
optim
base
type
elisa
grang
et
al
thiha
ibrahim
four
elisa
method
direct
elisa
delisa
use
competit
unwant
protein
plastic
bind
spot
antigen
attach
solid
phase
follow
enzymelabel
antibodi
assay
use
detect
variou
pathogen
antigen
brasino
et
al
indirect
elisa
ielisa
use
antigen
attach
solid
phase
follow
addit
unlabel
primari
antibodi
instead
peroxidas
enzymeconjug
secondari
antibodi
ad
onto
first
antibodi
ielisa
use
detect
specif
antibodi
sera
peng
et
al
competit
elisa
celisa
use
detect
small
molecul
lack
multipl
epitop
specif
antibodi
analyt
interest
immobil
microtit
plate
enzymeconjug
antigen
incub
captur
antibodi
antigen
unconjug
form
step
yield
color
follow
addit
substrat
signal
produc
directli
proport
quantiti
conjug
enzym
bound
invers
proport
quantiti
unconjug
antigen
present
dupontdeshorgu
et
al
sandwich
elisa
selisa
use
larger
protein
multipl
epitop
two
antibodi
use
consecut
captur
antibodi
immobil
microtit
plate
unknown
known
sampl
ad
matrix
minim
attach
solid
phase
peroxidaseenzym
label
antibodi
ad
color
directli
proport
amount
antigen
present
qu
et
al
elisa
extens
use
detect
variou
patholog
antigen
viral
bacteri
fungal
protozoa
algal
numer
sourc
thavaselvam
vijayaraghavan
improv
elisa
use
detect
antimelanoma
differentiationassoci
gene
antibodi
express
patient
dermatomyos
clinic
studi
newli
develop
elisa
exhibit
effici
detect
antibodi
show
promis
potenti
assist
routin
clinic
check
antibodi
patient
suppos
dm
sato
et
al
western
blot
assay
wba
also
call
immunoblot
techniqu
use
determin
molecular
weight
amount
relev
protein
present
sampl
protein
sampl
first
separ
electrophoresi
transfer
nitrocellulos
polyvinyliden
difluorid
pvdf
membran
detect
bound
primari
protein
antibodi
specif
protein
interest
ness
et
al
nonspecif
site
membran
block
bsa
nonfat
milk
powder
casein
final
label
secondari
antibodi
ad
detect
chemiluminesc
fluoresc
lewi
et
al
wba
use
confirm
presenc
purifi
protein
produc
variou
patholog
antigen
lethal
toxin
clostridium
sordellii
arya
et
al
shiga
toxin
skinner
et
al
staphylococcu
aureu
alphahemolysin
alphatoxin
ladhani
et
al
selenocosmia
huwena
huwentoxiniv
hwtxiv
yu
et
al
v
parahaemolyticu
thermolabil
hemolysin
tlh
wang
et
al
dot
blot
db
assay
use
measur
protein
concentr
semiquantit
slightli
differ
wba
protein
sampl
separ
electrophoresi
spot
directli
membran
hybrid
antibodi
probe
emmerich
cohen
techniqu
cost
effect
use
avidinbiotin
technolog
diaminobenzidin
chromogen
use
analysi
quantit
protein
cerebrospin
fluid
csf
sampl
case
creutzfeldtjakob
diseas
cjd
diseas
control
neurodegen
diseas
alzheim
diseas
ad
parkinson
diseas
pd
subramanian
et
al
immunohistochemistri
ihc
use
detect
identif
protein
local
tissu
essenti
retain
morpholog
tissu
cell
avail
antigen
site
fresh
rapidli
frozen
tissu
section
prefer
use
ihc
chemic
fix
tissu
formalin
embed
wax
zhu
et
al
addit
fix
crosslink
amino
acid
tissu
block
access
epitop
site
prevent
action
protein
specif
antibodi
exposur
hidden
epitop
region
perform
digest
enzym
heat
treatment
remov
endogen
peroxidas
activ
nonspecif
site
block
label
antibodi
unlabel
primari
antibodi
specif
protein
interest
use
follow
addit
secondari
label
antibodi
specif
primari
antibodi
diorio
et
al
ihc
recent
use
determin
identif
express
protein
lysosomeassoci
protein
beta
associ
prognosi
sever
human
malign
xiao
et
al
glucagonlik
renal
tubular
injuri
guo
et
al
transmembran
protein
induc
express
activ
matrix
metalloproteinas
mmp
dana
et
al
immunoprecipit
ip
use
studi
proteinprotein
interact
specif
enzym
activ
posttransl
modif
protein
quantif
determin
molecular
weight
protein
antigen
techniqu
includ
antibodyantigen
purif
complex
condit
specif
bind
antibodi
rare
protein
accumul
ip
dwane
kieli
luciferas
immunoprecipit
system
lip
develop
rapid
detect
antibodi
pest
de
petit
rumin
viru
pprv
berguido
et
al
varicellazost
viru
vzv
cohen
et
al
zinc
transport
autoantibodi
ustinova
et
al
pancreat
duoden
homeobox
autoantibodi
paa
donelan
et
al
flow
cytometri
fc
use
studi
antibodi
cell
surfac
relat
physiochem
properti
techniqu
develop
year
ago
robinson
et
al
allow
rapid
detect
variou
protein
cell
protein
produc
fluoresc
scatter
light
pass
machin
sens
point
gener
quantit
data
larg
number
cell
label
antibodi
use
detect
target
protein
molecul
antigen
surfac
cell
et
al
fc
use
visual
pulmonari
clearanc
zhou
et
al
fluoresc
decay
lifetim
control
sort
houston
et
al
quantif
dnaend
resect
mammalian
cell
forment
et
al
microspherebas
proteas
assay
highthroughput
screen
saunder
et
al
botulinum
neurotoxin
type
light
chain
proteas
inhibitor
saunder
et
al
fluoresc
activ
cell
sort
fac
use
detect
specif
cell
mix
popul
cell
base
distinct
fluoresc
light
scatter
characterist
yilmaz
et
al
techniqu
allow
isol
cell
flow
cytometri
fac
use
isol
highlipid
strain
tetraselmi
suecica
montero
et
al
highlipid
mutant
nannochloropsi
doan
obbard
e
coli
ozawa
et
al
highlipid
chlamydomona
mutant
terashima
et
al
chlorella
manandharshrestha
hildebrand
addit
technolog
use
quantif
cellular
uptak
cellpenetr
peptid
mrna
date
et
al
enzym
link
immunospot
elispot
assay
use
monitor
cellular
immun
respons
human
anim
whitesid
et
al
involv
polyvinyliden
difluorid
pvdf
assist
microtit
plate
precoat
antibodi
specif
antigen
interest
captur
antibodi
bind
analyt
interest
precis
condit
biotinyl
antibodi
specif
analyt
interest
ad
detect
origin
antibodi
wash
remov
cell
debri
final
enzym
label
conjug
ad
second
wash
remov
unbound
antibodi
visual
color
product
product
typic
black
spot
repres
singl
cell
produc
antigen
interest
janetzki
et
al
techniqu
use
develop
coxsackieviru
neutral
test
hou
et
al
determin
rotaviru
infect
li
et
al
diagnost
applic
includ
diagnos
sensit
hous
dust
mite
chang
et
al
pulmonari
tuberculosi
pang
et
al
pleural
tuberculosi
adilistya
et
al
smearneg
tuberculosi
li
et
al
spinal
tuberculosi
yuan
et
al
cytomegaloviru
infect
nesher
et
al
later
flow
immunochromatograph
test
lft
simpl
cost
effect
devic
use
detect
presenc
absenc
target
antigen
wide
use
medic
diagnost
home
pregnanc
test
laboratori
test
technolog
involv
transport
fluid
eg
urin
capillari
bed
fragment
porou
paper
microstructur
polym
sinter
polym
hansson
et
al
techniqu
compris
variou
compon
step
sampl
pad
act
spong
absorb
fluid
fluid
migrat
conjug
pad
contain
protein
conjug
immobil
surfac
bioactiv
particl
saltsugar
matrix
react
antigen
next
sampl
fluid
dissolv
conjug
saltsugar
matrix
antibodyparticl
fluid
mix
flow
porou
structur
caus
analyt
bind
particl
migrat
third
capillari
bed
final
third
captur
molecul
stripe
area
bind
fluid
mix
contain
analyt
particl
consequ
chang
color
yu
et
al
lft
use
competit
sandwich
assay
latex
blue
color
nanometers
particl
gold
red
color
fluoresc
magnet
label
particl
also
use
seydack
techniqu
qualit
nevertheless
quantiti
analyt
sampl
measur
intens
test
line
color
usual
carri
optic
nonopt
later
flow
reader
biosensor
lfb
complementari
metaloxid
semiconductor
cmo
chargecoupl
devic
ccd
magnet
immunoassay
mia
gui
et
al
progress
hybridoma
technolog
product
highli
specif
mab
revolution
therapeut
use
antibodi
diagnosi
cure
infect
develop
vaccin
antigen
character
genet
manipul
antibodi
widespread
applic
diagnost
therapeut
target
dd
potent
pathogen
cancer
physiolog
disord
tiwari
et
al
use
diagnosi
lymphoid
myeloid
malign
tissu
character
elisa
radiolabel
immunoassay
serotyp
microb
addit
use
diagnosi
immunolog
interpol
passiv
antibodi
antiidiotyp
suppress
magic
bullet
treatment
cytotox
agent
coupl
antimous
specif
antibodi
keller
stiehm
similarli
recombin
dna
technolog
rdna
revolution
reconstruct
mab
genet
engin
use
chimer
antibodi
human
antibodi
cdr
graft
antibodi
therapeut
use
dimitrov
mark
shen
et
al
fit
et
al
molecular
imag
provid
sensit
noninvas
method
molecular
character
cell
surfac
phenotyp
diseas
diagnosi
treatment
rapidli
grow
multidisciplin
involv
molecular
biolog
immunolog
medicin
massoud
gambhir
therapeut
applic
antibodi
includ
clinic
diagnosi
treatment
hematolog
cardiolog
immunolog
autoimmun
infecti
diseas
oncolog
neve
kwok
mab
use
molecular
imag
probe
investig
cell
surfac
vivo
coupl
cell
surfac
target
advanc
antibodi
technolog
facilit
product
antibodi
optim
noninvas
imag
man
et
al
numer
applic
radioimmunoscintigraphi
antibodybas
positron
emiss
tomographi
immunopet
singlephoton
emiss
comput
tomographi
spect
spet
knowl
wu
antibodi
protect
host
invad
microb
natur
vaccin
neutral
toxin
induc
microbicid
effector
function
antibodymedi
identif
pathogen
infect
essenti
reveal
immunoprotect
respons
host
sharon
et
al
b
cell
epitop
variabl
region
protect
antibodi
contact
infecti
antigen
map
import
develop
effect
vaccin
support
serodiagnost
techniqu
identifi
protect
epitop
vaccin
develop
estim
convent
vaccin
kill
attenu
pathogen
malito
et
al
b
cell
epitop
conform
determin
pepscan
techniqu
led
develop
antibodi
therapeut
vaccin
design
recognit
protect
antibodi
respons
ahmad
et
al
techniqu
also
target
pathogen
novel
antimicrobi
exampl
includ
vshape
glycan
epitop
oantigen
francisella
tularensi
peptid
epitop
influenza
viru
glycopeptid
epitop
loop
hiv
type
sharon
et
al
peptid
screen
biopan
antibodi
sera
variou
human
diseas
includ
sever
acut
respiratori
syndrom
sar
human
papillomaviru
hpv
avian
influenza
virus
aiv
moreov
peptidebas
antigen
also
use
serolog
diagnosi
develop
vaccin
wu
et
al
surfac
plasmon
reson
spr
techniqu
first
use
year
epitop
map
polysaccharid
l
pneumophila
epitop
map
variou
low
affin
peptideprotein
interact
spr
analog
work
principl
elisa
techniqu
label
free
techniqu
screen
molecular
interact
realtim
complex
physic
principl
bind
recombin
peptideprotein
analyz
natur
ligand
mab
spr
use
epitop
map
vitamin
holotranscobalamin
hemophilia
diseas
ricin
toxin
manganes
transport
protein
c
mntc
staphylococcu
sp
also
identifi
goodpastur
autoimmun
diseas
epitop
combin
pdt
nguyen
et
al
phage
display
pan
method
fail
yield
specif
result
presenc
parasit
phage
clone
often
remov
wash
overcom
limit
next
gener
sequenc
ng
technolog
use
sequenc
sublibrari
biopan
experi
naqid
et
al
next
gener
phage
display
ngpd
sequenc
million
read
per
pan
round
method
rapid
compar
tradit
elisa
screen
ngpd
use
identifi
target
specif
ligand
singl
pan
round
use
librari
ligand
motif
ravn
et
al
techniqu
widespread
applic
identif
thousand
ligand
map
antibodi
respons
infecti
particl
clinic
target
antigenrel
ligand
discov
help
genet
encod
peptid
librari
correspondingli
ligand
select
use
ngpd
detect
low
abund
copi
clone
without
numer
round
select
subsequ
ng
facilit
quantif
gene
express
genom
assembl
metagenom
analysi
addit
use
pdt
ion
torrent
techniqu
matochko
derda
antibodi
critic
immun
infecti
diseas
extens
use
prevent
treatment
infect
caus
bacteria
viru
infecti
agent
improv
public
health
emil
von
behr
award
first
nobel
prize
physiolog
medicin
discoveri
serum
therapi
diphtheria
led
term
antitoxin
later
name
translat
antibodi
paul
erlich
paper
graham
ambrosino
emerg
recombin
technolog
revolution
select
human
develop
therapeut
antibodi
permit
strateg
design
antibodybas
element
specif
divers
number
genet
engin
mab
use
treatment
numer
infecti
diseas
hudson
souriau
ebola
viru
diseas
evd
sever
often
fatal
zoonot
infect
document
recent
widespread
outbreak
west
africa
caus
viru
filovirida
famili
genu
ebolaviru
diseas
transmit
human
human
via
contact
bodi
fluid
patient
incub
period
day
case
fatal
rate
rang
beech
et
al
mab
name
zmapp
manufactur
tobacco
plant
nicotiana
benthamiana
treat
evd
patient
improv
public
health
contain
cocktail
differ
mab
zmab
work
avert
spread
diseas
within
bodi
qiu
et
al
recent
studi
investig
treatment
evd
patient
zmapp
buffi
coat
transfus
ebola
survivor
broadspectrum
antivir
patient
first
neonat
document
success
surviv
evd
et
al
therapeut
antibodi
gener
fight
sever
infecti
cancer
cancer
group
diseas
involv
abnorm
cell
growth
prolifer
caus
alter
mutat
genet
materi
cell
cell
outgrowth
lump
may
benign
metastat
marusyk
polyak
cancer
outpac
immun
system
avoid
detect
block
immun
system
activ
thu
numer
therapeut
antibodi
necitumumab
ramucirumab
ganitumab
cixutumumab
biib
mapatumumab
trebananib
carlumab
investig
success
treatment
human
cancer
malign
includ
nsclc
metastat
gastric
adenocarcinoma
brain
metastasi
breast
ovarian
periton
fallopian
tube
prostat
pancreat
colorect
cancer
melanoma
eye
liver
nonhodgkin
lymphoma
multipl
myeloma
dantasbarbosa
et
al
nixon
et
al
similarli
engin
antibodi
use
treatment
variou
type
arthriti
arthriti
greek
word
joint
chronic
multifactori
diseas
immun
system
attack
start
degrad
bodi
joint
persidi
therapeut
antibodi
adalimumab
mavrilimumab
develop
treatment
rheumatoid
arthriti
juvenil
idiopath
arthriti
psoriat
arthriti
ankylos
spondyl
dantasbarbosa
et
al
nixon
et
al
therapeut
antibodi
develop
treatment
infecti
diseas
includ
prophylaxi
anthrax
autoantibodyposit
lupu
angioedema
immun
thrombocytopen
purpura
macular
degener
hemophilia
psoriasi
alzheim
muscl
loss
weak
optic
neuriti
ulcer
coliti
pulmonari
fibrosi
asthma
dantasbarbosa
et
al
nixon
et
al
prognosi
diseas
complex
process
involv
deduct
sever
observ
symptom
choic
treatment
base
therapeut
effect
antibodi
exquisit
specif
mab
gener
exhibit
greater
specif
therefor
use
wide
varieti
assay
format
diagnosi
treatment
infecti
diseas
zola
thomson
moreov
show
rapid
identif
new
rare
infecti
agent
import
public
health
measur
shortli
develop
novel
mab
help
monitor
lessen
likelihood
epidem
diseas
threat
impos
human
health
preval
infecti
agent
zola
et
al
past
decad
antibodi
develop
use
convent
techniqu
hybridoma
signific
applic
therapeut
howev
recent
advanc
recombin
technolog
enhanc
gener
effici
immunoglobulin
fragment
antibodi
engin
offer
rapid
costeffect
effici
biomed
tool
discoveri
highaffin
peptidesprotein
investig
proteinprotein
interact
receptor
bind
epitop
identif
power
technolog
use
varieti
system
approach
differ
question
background
cell
biolog
biotechnolog
moreov
use
product
differ
type
engin
antibodi
target
molecul
highli
uniqu
conserv
antigen
addit
facilit
diagnosi
treatment
infect
improv
human
health
antibodi
engin
possess
broad
spectrum
biolog
biotechnolog
medic
antibodi
applic
develop
novel
therapeut
variou
diseas
field
numer
novel
therapeut
drug
develop
vitro
screen
select
techniqu
base
sever
high
throughput
immun
effector
function
engin
antibodi
highaffin
antibodi
fragment
review
comprehens
describ
hybridoma
technolog
advanc
antibodi
engin
techniqu
engin
antibodi
antibodi
fragment
display
technolog
applic
antibodi
conclus
studi
help
understand
signific
antibodi
fabric
approach
extens
use
molecular
immunolog
diagnost
imag
biomed
biotechnolog
field
pursu
healthier
futur
human
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
